»

[nahoma8]

It is listed under otc - NRIFF, or TSE:NRI. There is small difference in stock price because of currency difference between Canada and US. It may be good to get in and wait for August approval.

Link: NRI,NRIFF FDA Accepts Nuvo's Resubmission For Pennsaid(R)

The FDA decision by August 5, 2009 (the "PDUFA Date") under the Prescription Drug User Fee Act.
Good Luck

[nahoma8]

BiomedReports has also put it on their homepage today with other Pharama lists. It can be the next Neph or Heb. I had some positions in both and also bought from NRIFF.

Links: 13 Extreme FDA Trades: BioMedReports.com 6/1/09 Update - BioMedReports.com

Nuvo Research (PINK:NRIFF) (TSE:NRI): Expected PDUFA decision date of 8/5/09 for the Company's NDA re-submission for Pennsaid, which is a topical NSAID for arthritis pain and inflammation.

[GazD]

Some info about their Phase 3.

The subject of the PAIN article is Nuvo’s Phase 3 trial, Study 112, which enrolled 775 patients in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. Patients in this five-arm, double-blind, 12-week trial applied a topical solution and took an oral pill. The five arms were: 1) Pennsaid plus oral placebo, 2) topical placebo containing a small amount of DMSO for blinding purposes (DMSO facilitates delivery of diclofenac to the knee) plus oral placebo, 3) topical vehiclecontrol (containing the same concentration of DMSO as in Pennsaid) plus oral placebo, 4) topical placebo plus oral diclofenac and 5) Pennsaid plus oral diclofenac. Pennsaid (arm 1) was superior to placebo (arm 2) with statistically significant improvement in all three primary clinical endpoints required by the FDA: pain relief (p=0.019), improvement in physical function (p=0.046) and improved patient overall health assessment (POHA) (p<0.0001). Additional results from the trial show that Pennsaid (arm 1) was superior to vehicle control (arm 3) (pain, p=0.009; physical function, p=0.026; POHA, p=0.016). There was no difference between vehicle control (arm 3) and placebo (arm 2) indicating that DMSO alone is ineffective against the symptoms of knee osteoarthritis (p>0.05). There was no difference between Pennsaid (arm 1) and oral diclofenac (arm 4) for all three efficacy endpoints (p>0.05). Arm 5 was included in the trial at the FDA’s request to review the side effect profile of Pennsaid if combined with an oral NSAID. This combination showed no increased incidence of the usual systemic side effects, just the expected additive profiles of Pennsaid alone plus oral diclofenac alone. Dry skin was the most common adverse event with Pennsaid use. Fewer digestive system adverse events and laboratory abnormalities (decreased hemoglobin and increased AST, ALT and creatinine) were observed with Pennsaid as compared to oral diclofenac.

Source: http://www.nuvoresearch.com/investor...0Published.pdf

[ahlavanthan]

This is also followed over on the Canadian side under symbol : NRI

http://www.stockrants.com/forum/cana...earch-inc.html

[Aaron]

<---interested, but would like to see a small pullback, i'll be watching :) thanks for the tip.

[bondo26]

NRIFF always trades with much lower volume than NRI. But this is another perfect buy low early and let it run up close to approval date, grab your intial investment back and ride free shares.

[mahmissa]

anyone watching the NEPH run?

[schwi105]

Good little run so far today. Watch this stock closely if you are planning on getting in before FDA. NRI.TO NRIFF.PK

Darin

[GypsyDRB]

Originally Posted by mahmissa anyone watching the NEPH run?

sold 20k shares of NEPH at .885 to cover a margin call and pay back some additional monies I owed .

still strong with 30,000 though through FDA decision.

[Spinner]

Originally Posted by schwi105 Good little run so far today. Watch this stock closely if you are planning on getting in before FDA. NRI.TO NRIFF.PK

Indeed, I offloaded a stack above CDN$0.30, will increase my position on any pullbacks.

This stock is showing a lot of movement early in the game with almost two months still to run!

Cheers, Spinner